NASDAQ$DH
Definitive Healthcare Corp · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Definitive Healthcare's financial results for Q1 2023 were reported, showing revenue growth and strategic customer wins.
Definitive Healthcare reported a solid start to 2023 with an 18% increase in revenue compared to Q1 2022, reaching $59.2 million. The company experienced a net loss of $15.6 million, while adjusted EBITDA stood at $15.7 million, representing 26% of revenue. Customer wins and product innovations were also highlighted.
- Revenue increased by 18% year-over-year, reaching $59.2 million.
- Net loss was ($15.6) million, representing 26% of revenue.
- Adjusted EBITDA was $15.7 million, or 26% of revenue.
- Unlevered free cash flow was $20.4 million, or 34% of revenue.
Headline financials
Revenue & EPS history
Definitive Healthcare · Revenue · Quarterly
$59.2M
Forward guidance
Definitive Healthcare provided financial guidance for the second quarter and full year of 2023.
Tailwinds
- Second quarter revenue is expected to be in the range of $60.5 – $61.5 million, a 12% increase year over year.
- Second quarter Adjusted Operating Income is expected to be in the range of $14.5 – $15.5 million.
- Second quarter Adjusted EBITDA is expected to be in the range of $16.0 – $17.0 million.
- Second quarter Adjusted Net Income is expected to be $7.0 – $8.0 million.
- Full year revenue is expected to be in the range of $249.0 – $255.0 million, up 12% – 15% from prior year.
Headwinds
- The company notes ongoing macroeconomic challenges.
- Full year Adjusted Operating Income is expected to be in the range of $61.5 – $65.5 million.
- Full year Adjusted EBITDA is expected to be in the range of $67.0 – $71.0 million.
- Full year Adjusted Net Income is expected to be $30.0 – $34.0 million.
- Future performance is subject to uncertainties, risks, and changes in circumstances that are difficult to predict.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2023
-3.2%
Avg return
Earnings day
-5.7%
Avg return
5 days after
-5.8%
Avg return
30 days after
39%
7 / 18 earnings
Positive
+31.7%
Q1 2025
Best reaction
-34.3%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.2% | -2.0% | -5.2% | |
| Q4 2025 | -8.6% | -12.9% | -25.0% | |
| Q3 2025 | +11.9% | +2.6% | -6.4% | |
| Q1 2025 | +31.7% | +21.4% | +33.1% | |
| Q4 2024 | -34.3% | -43.7% | -40.2% | |
| Q3 2024 | -1.4% | +6.3% | +8.4% | |
| Q2 2024 | -1.4% | +5.1% | +21.6% | |
| Q1 2024 | -27.1% | -27.5% | -22.9% | |
| Q4 2023 | +2.3% | -4.2% | -13.3% | |
| Q3 2023 | +27.5% | +29.5% | +49.5% | |
| Q2 2023 | -4.0% | -6.2% | -21.2% | |
| Q1 2023 | +0.9% | -3.7% | +7.9% | |
| Q4 2022 | +3.5% | -1.6% | -11.5% | |
| Q3 2022 | -25.0% | -29.7% | -14.5% | |
| Q2 2022 | -16.3% | -18.6% | -35.7% | |
| Q1 2022 | -17.5% | -31.3% | -19.4% | |
| Q4 2021 | +7.6% | +13.6% | +14.0% | |
| Q3 2021 | -5.8% | +0.2% | -23.3% | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro